
Breakthrought Solutions for Effective Therapies

Oncology
Anti-Cancer Solutions Targeting metastasis, failure and drug resistance

Obesity
Preventing cancers by Treating Obesity

Viral Infection
Example : targeting adipose tissue HIV reservoir and Covid19
About us
THERANOVIR is a young innovative Health-Tech company of Reserach and Devlopment of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patent in January 2023.
THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.
Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex

Theranovir rewards
THERANOVIR is a winner of :
- Lab-SHAKER 2017 (Genopole),
- Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
- HEC-Challenge+ 2019 (HEC Paris),
- Ilab 2020 (Ministry of education and research),
- Innov’up PIA 2021 (Ile-de-France region) competitions.
Team

Zakia BELAID-SANDAL (PhD)
Co-founder-President / CEO/CSO
17 years of experience in leading and participating in oncology programs in France and abroad
3 co-invented patents

Elie MATTA (PhD)
Assistant Scientific Investigator
PhD in Oncology and Cancer Biology
Co-auteur of 3 publications in DNA Repair
They support us
THERANOVIR is looking for seed funds between Q2 and Q3 2023 allowing it to select the lead and enter the regulatory CMC phase
Labels



Contact
Head Office
Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes
Laboratory R&D
Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif
contact@theranovir.com
Phone
+ 33 1 42 11 60 43